CSLLY logo

CSLLY CSL Limited

Other OTC · Biotechnology · Healthcare

$32.39
-0.62 (-1.88%)

CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segment…

Market Cap: $125.42Bwww.csl.com

Price

No data yet.

Social Signal Score

47
5d
—
30d
60
1 mentions
—
60d
40
7 mentions
—
90d
41
8 mentions
—
news: 8

Analyst Ratings

Avg price target$153.5+373.9%
Low $153.5Median $153.5High $153.5
Current Consensus

Revenue

$7.44B+552.15%
$1.14B$3.55B$5.96B$8.36B
Dec 2006Jun 2026

Analyst Estimates

FY2025
$3.63
$3.30–$4.29
2 analysts
FY2026
$1.57-57% YoY
$1.54–$1.59
1 analysts
FY2027
$1.56-1% YoY
$1.54–$1.58
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Gordon Naylor DipCompSc
Sector
Healthcare
Industry
Biotechnology
Employees
29,000
Beta
0.08
Country
AU
Piotroski score
5 / 9 (Middling)
Altman Z-score
6.00
www.csl.com